Pharmafile Logo
Pharmafocus logo
Advanced Search

GSK

Showing 15 posts of 760 posts found.

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025
Regulatory Affairs, Research and Development Asthma & COPD, GSK

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …

News

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025
Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …

Appointment

Multiple myeloma treatment approved in Japan

May 21, 2025
Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …

News

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024
Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …

News
Press release

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024
Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …

News

GSK’s application for Blenrep for MM treatment accepted for EMA review

July 19, 2024
Medical Communications Blenrep, EMA, GSK, Oncology

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …

News

GSK and CureVac to restructure collaboration into licensing agreement

July 3, 2024
Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration

GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …

News

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024
Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …

News

GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients

June 10, 2024
Medical Communications FDA, GSK, Immunology, Vaccine

GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) …

News

GSK shares positive results from phase 3 asthma trials

May 21, 2024
Research and Development Asthma & COPD, GSK, asthma, clinical trial

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

News

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024
Research and Development AMR, Fleming Initiative, GSK, Microbiology, funding

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …

News

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024
Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …

News

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024
Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …

News

GSK’s meningococcal vaccine candidate accepted for FDA review

April 16, 2024
Medical Communications FDA, GSK, Immunology, meningococcal

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …

News

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

March 18, 2024
Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025